PRESS RELEASE published on 03/28/2026 at 16:00, 2 months 23 days ago Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute à l'American Academy of Dermatology (AAD) de 2026 Étude Clinique Sanofi Phase 3 Dermatite Atopique Amlitelimab
PRESS RELEASE published on 03/28/2026 at 16:00, 2 months 23 days ago Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Positive results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented at AAD Annual Meeting, showing progressive efficacy with Q12W dosing potential Sanofi Phase 3 Atopic Dermatitis Amlitelimab Q12W
BRIEF published on 03/27/2026 at 13:05, 2 months 24 days ago Sanofi : Approbation UE recommandée pour Sarclisa sous-cutané Sanofi Myélome Multiple Sarclisa CHMP Injecteur Portable
BRIEF published on 03/27/2026 at 13:05, 2 months 24 days ago Sarclisa SC de Sanofi recommandé pour une approbation européenne Sanofi Myélome Multiple Approbation De L'UE Sarclisa SC Injecteur Corporel
BRIEF published on 03/27/2026 at 13:05, 2 months 24 days ago Sanofi: EU approval recommended for subcutaneous Sarclisa Sanofi Multiple Myeloma Sarclisa CHAMP Portable Injector
BRIEF published on 03/27/2026 at 13:05, 2 months 24 days ago Sanofi's Sarclisa SC Recommended for EU Approval Sanofi Multiple Myeloma EU Approval Sarclisa SC On-Body Injector
PRESS RELEASE published on 03/27/2026 at 13:00, 2 months 24 days ago Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Sanofi's Sarclisa subcutaneous formulation via on-body injector recommended for EU approval by CHMP for multiple myeloma treatment, offering innovative delivery. Final decision expected soon Multiple Myeloma Sarclisa CHMP Recommendation On-Body Injector Subcutaneous Formulation
PRESS RELEASE published on 03/27/2026 at 13:00, 2 months 24 days ago Communiqué de presse : La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple Sanofi's Sarclisa subcutaneous formulation, recommended by CHMP for approval in the EU for multiple myeloma treatment. Positive results show efficacy & safety. First portable anticancer treatment with on-body injector Sanofi Multiple Myeloma Sarclisa CHMP Subcutaneous
BRIEF published on 03/24/2026 at 07:35, 2 months 28 days ago Sanofi publie un aide-mémoire du premier trimestre 2026 pour soutenir l'analyse financière Innovation Biopharma Sanofi Modélisation Financière Résultats Du T1 2026
BRIEF published on 03/24/2026 at 07:35, 2 months 28 days ago Sanofi's Q1 2026 financial guide is now online Investors Quarterly Results Sanofi Financial Document Q1 2026
Published on 06/20/2026 at 01:00, 1 day 10 hours ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 11 hours ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 2 days 7 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days 10 hours ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days 10 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 21:25, 14 hours 28 minutes ago VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 1 day 5 hours ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 1 day 15 hours ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 1 day 15 hours ago 2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 1 day 16 hours ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 1 day 16 hours ago Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 1 day 16 hours ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 1 day 16 hours ago Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 1 day 16 hours ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026